Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Cooperation with Companies Is Essential: RIKEN Researcher
January 15, 2001
- Sales of Takeda's Blopress Skyrocket: Top 100 Products Ranking
January 15, 2001
- Tissue Engineering Chair Donated by BCS at Tokai Univ.
January 15, 2001
- NHI Price System Reform Shelved in Japan: US ITC Report
January 15, 2001
- BUSINESS NEWS IN BRIEF
January 1, 2001
- Tsuruha Acquires Drug Tomato in Iwate
January 1, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 1, 2001
- Kaletra Included in NHI List
January 1, 2001
- Fukuda Denshi to Charge Customers for Maintenance Services
January 1, 2001
- Welfide Licenses Glaucoma Treatment to Senju
January 1, 2001
- NHI Price Listing of Relenza, Tamiflu No Sooner Than Mid February
January 1, 2001
- OTC NEWS IN BRIEF
January 1, 2001
- New Year's Greeting
January 1, 2001
- Ministries, Agencies to Be Reorganized
January 1, 2001
- Many Know about Anti-smoking Aids, But They Are Not Commonly Used: Survey
January 1, 2001
- The Year 2000 in RetrospectJapanese Drug Industry at the Mercy of Large Waves of Globalization
January 1, 2001
- CST Report Urges Strengthening Lifestyle-related Disease Research
January 1, 2001
- Hitachi to Provide High Tech Healthcare Services
January 1, 2001
- 'New Opportunities and New Solutions Are within Reach'
January 1, 2001
- REGULATORY NEWS IN BRIEF
January 1, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…